SynthesisOncotarget2016
Quantitative assessment of polymorphisms in H19 lncRNA and cancer risk: a meta-analysis of 13,392 cases and 18,893 controls.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis.BMC cancer · 2023Pooled it
- Pooled it
- Pooled it
- Association between lncRNA H19 rs217727 polymorphism and the risk of cancer: an updated meta-analysis.BMC medical genetics · 2019Pooled it
- Significant association between lncRNA H19 polymorphisms and cancer susceptibility: a meta-analysis.Oncotarget · 2017Pooled it
- The Role of lncRNA Polymorphisms in Digestive System Cancers: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Article
- Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors.Clinical and experimental medicine · 2023Review
- Long noncoding RNA (lncRNA)Genes & diseases · 2023Review
- Impact of rs2107425 Polymorphism and Expression of lncH19 and miR-200a on the Susceptibility of Colorectal Cancer.Indian journal of clinical biochemistry : IJCB · 2023Article
- Significant Associations of lncRNA H19 Genotypes with Susceptibility to Childhood Leukemia in Taiwan.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Dexamethasone can attenuate the pulmonary inflammatory response via regulation of the lncH19/miR-324-3p cascade.Journal of inflammation (London, England) · 2021Article
- Association between lncRNA-H19 polymorphisms and hepatoblastoma risk in an ethic Chinese population.Journal of cellular and molecular medicine · 2021Article
- TheBioMed research international · 2020Article
- Significance of Single-Nucleotide Variants in Long Intergenic Non-protein Coding RNAs.Frontiers in cell and developmental biology · 2020Review
- Association of lncRNAGenes · 2019Article
- Functional polymorphisms of the lncRNACancer cell international · 2019Article
- Long Non-Coding RNAs in Obesity-Induced Cancer.Non-coding RNA · 2018Review
- Genetic variants in lncRNAOncotarget · 2018Article
- Prognostic and clinicopathological significance of long noncoding RNA HOXA11-AS expression in human solid tumors: a meta-analysis.Cancer cell international · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
H19 refers to a long non-coding RNA (lncRNA) that functions as an oncogenic molecule in different cancer cells. Genetic variants of H19 may affect the activity of certain regulatory factors, which subsequently regulate the aberrant expression of H19. This feedback loop might be one of the underlying mechanisms influencing tumour susceptibility and prognosis. Although there have been several recent studies that examined possible links between polymorphisms in H19 and cancer risk, the results have been inconclusive. Thus, we performed a meta-analysis to estimate the associations between H19 polymorphisms (rs2107425, rs2839698 and rs217727) and cancer risk. Ten studies comprising 13,392 cases and 18,893 controls were included in the study. Overall, the variant T allele of rs2107425 correlated with a significantly decreased risk of developing cancer (dominant model: OR = 0.86; 95% CI = 0.76-0.98). In addition, a marginally significant association between the rs2839698 and cancer risk was observed (dominant model: OR = 1.09; 95% CI = 0.99-1.20). After stratification for ethnicity, it became apparent that Asians with the variant A allele of rs2839698 exhibited a significantly higher risk of developing cancer (dominant model: OR = 1.11; 95% CI = 1.01-1.23). Interestingly, the rs2839698 variant was also significant associated with an increased risk of cancers of the digestive system (dominant model: OR = 1.23; 95% CI = 1.08-1.41). These findings provided evidence that H19 rs2107425 may modify general cancer susceptibility, while rs2839698 may modify cancer susceptibility based on ethnicity and type. Further experimental studies to evaluate the limits of this hypothesis are warranted, and future functional studies are required to clarify the possible mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.